Akouos to Present at Upcoming August Virtual Investor Conferences

Rhea-AI Summary

Akouos, a precision genetic medicine company, will have its CEO, Manny Simons, present at two virtual investor conferences in August 2021. The first is the BTIG Biotechnology Conference on August 10 at 2:30 p.m. EDT, followed by the Canaccord Genuity 41st Annual Growth Conference on August 12 at 12:00 p.m. EDT. Interested investors can access the live webcast via Akouos's website, with an archived replay available for 90 days. Akouos focuses on developing gene therapies for individuals with disabling hearing loss, leveraging a proprietary AAV vector library.

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will present at two upcoming virtual investor conferences in August:

• BTIG Biotechnology Conference. Fireside chat on Tuesday, August 10 at 2:30 p.m. EDT
  
• Canaccord Genuity 41^st Annual Growth Conference. Fireside chat on Thursday, August 12 at 12:00 p.m. EDT

A live webcast of the Canaccord fireside chat will be accessible through the investors section of www.akouos.com. To access the webcast, please go to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. An archived replay will be available on Akouos’s website for 90 days following the conference.

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Contacts

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com

FAQ

What are the dates for Akouos's investor presentations in August 2021?

Akouos will present at the BTIG Biotechnology Conference on August 10 and the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021.

What time will Manny Simons present at the BTIG Biotechnology Conference?

Manny Simons will present at the BTIG Biotechnology Conference on August 10, 2021, at 2:30 p.m. EDT.

How can I access the Canaccord Genuity conference webcast for Akouos?

The Canaccord Genuity conference webcast for Akouos can be accessed through their website approximately 15 minutes before the presentation.

What is Akouos's focus in gene therapy?

Akouos is dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals with disabling hearing loss.

Where is Akouos headquartered?

Akouos is headquartered in Boston.